Live feed
Filing
SC 13D
SC 13D0001213900-24-015480·BridgeBio Oncology Therapeutics, Inc.
Schedule 13D ownership disclosure
HELIX ACQUISITION CORP II
Security class unavailable · CUSIP: G4444H101
Event date: 2024-02-13
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 21.4000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-24-015480
- Form type
- SC 13D
- Filer
- BridgeBio Oncology Therapeutics, Inc.
- CIK
- CIK 1869105
- Filed
- Feb 20, 2024
- Reporting period
- Feb 13, 2024
- Description
- Schedule 13D beneficial ownership